A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome

Christie M. Buchovecky, Stephen D. Turley, Hannah M. Brown, Stephanie M. Kyle, Jeffrey G. McDonald, Benny Liu, Andrew A. Pieper, Wenhui Huang, David M. Katz, David W. Russell, Jay Shendure, Monica J. Justice

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the most severe autism spectrum disorder. Re-expressing Mecp2 in symptomatic Mecp2-null mice markedly improves function and longevity, providing hope that therapeutic intervention is possible in humans. To identify pathways in disease pathology for therapeutic intervention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2-null mice and isolated five suppressors that ameliorate the symptoms of Mecp2 loss. We show that a stop codon mutation in Sqle, encoding squalene epoxidase, a rate-limiting enzyme in cholesterol biosynthesis, underlies suppression in one line. Subsequently, we also show that lipid metabolism is perturbed in the brains and livers of Mecp2-null male mice. Consistently, statin drugs improve systemic perturbations of lipid metabolism, alleviate motor symptoms and confer increased longevity in Mecp2 mutant mice. Our genetic screen therefore points to cholesterol homeostasis as a potential target for the treatment of patients with Rett syndrome.

Original languageEnglish (US)
Pages (from-to)1013-1020
Number of pages8
JournalNature Genetics
Volume45
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Rett Syndrome
Cholesterol
Lipid Metabolism
Hope
Squalene Monooxygenase
Methyl-CpG-Binding Protein 2
Ethylnitrosourea
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mutation
Terminator Codon
Mutagenesis
Homeostasis
Therapeutics
Pathology
Liver
Brain
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics

Cite this

A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. / Buchovecky, Christie M.; Turley, Stephen D.; Brown, Hannah M.; Kyle, Stephanie M.; McDonald, Jeffrey G.; Liu, Benny; Pieper, Andrew A.; Huang, Wenhui; Katz, David M.; Russell, David W.; Shendure, Jay; Justice, Monica J.

In: Nature Genetics, Vol. 45, No. 9, 09.2013, p. 1013-1020.

Research output: Contribution to journalArticle

Buchovecky, CM, Turley, SD, Brown, HM, Kyle, SM, McDonald, JG, Liu, B, Pieper, AA, Huang, W, Katz, DM, Russell, DW, Shendure, J & Justice, MJ 2013, 'A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome', Nature Genetics, vol. 45, no. 9, pp. 1013-1020. https://doi.org/10.1038/ng.2714
Buchovecky, Christie M. ; Turley, Stephen D. ; Brown, Hannah M. ; Kyle, Stephanie M. ; McDonald, Jeffrey G. ; Liu, Benny ; Pieper, Andrew A. ; Huang, Wenhui ; Katz, David M. ; Russell, David W. ; Shendure, Jay ; Justice, Monica J. / A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. In: Nature Genetics. 2013 ; Vol. 45, No. 9. pp. 1013-1020.
@article{62a2c9330ac349fbb546fef570dc1d55,
title = "A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome",
abstract = "Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the most severe autism spectrum disorder. Re-expressing Mecp2 in symptomatic Mecp2-null mice markedly improves function and longevity, providing hope that therapeutic intervention is possible in humans. To identify pathways in disease pathology for therapeutic intervention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2-null mice and isolated five suppressors that ameliorate the symptoms of Mecp2 loss. We show that a stop codon mutation in Sqle, encoding squalene epoxidase, a rate-limiting enzyme in cholesterol biosynthesis, underlies suppression in one line. Subsequently, we also show that lipid metabolism is perturbed in the brains and livers of Mecp2-null male mice. Consistently, statin drugs improve systemic perturbations of lipid metabolism, alleviate motor symptoms and confer increased longevity in Mecp2 mutant mice. Our genetic screen therefore points to cholesterol homeostasis as a potential target for the treatment of patients with Rett syndrome.",
author = "Buchovecky, {Christie M.} and Turley, {Stephen D.} and Brown, {Hannah M.} and Kyle, {Stephanie M.} and McDonald, {Jeffrey G.} and Benny Liu and Pieper, {Andrew A.} and Wenhui Huang and Katz, {David M.} and Russell, {David W.} and Jay Shendure and Justice, {Monica J.}",
year = "2013",
month = "9",
doi = "10.1038/ng.2714",
language = "English (US)",
volume = "45",
pages = "1013--1020",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome

AU - Buchovecky, Christie M.

AU - Turley, Stephen D.

AU - Brown, Hannah M.

AU - Kyle, Stephanie M.

AU - McDonald, Jeffrey G.

AU - Liu, Benny

AU - Pieper, Andrew A.

AU - Huang, Wenhui

AU - Katz, David M.

AU - Russell, David W.

AU - Shendure, Jay

AU - Justice, Monica J.

PY - 2013/9

Y1 - 2013/9

N2 - Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the most severe autism spectrum disorder. Re-expressing Mecp2 in symptomatic Mecp2-null mice markedly improves function and longevity, providing hope that therapeutic intervention is possible in humans. To identify pathways in disease pathology for therapeutic intervention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2-null mice and isolated five suppressors that ameliorate the symptoms of Mecp2 loss. We show that a stop codon mutation in Sqle, encoding squalene epoxidase, a rate-limiting enzyme in cholesterol biosynthesis, underlies suppression in one line. Subsequently, we also show that lipid metabolism is perturbed in the brains and livers of Mecp2-null male mice. Consistently, statin drugs improve systemic perturbations of lipid metabolism, alleviate motor symptoms and confer increased longevity in Mecp2 mutant mice. Our genetic screen therefore points to cholesterol homeostasis as a potential target for the treatment of patients with Rett syndrome.

AB - Mutations in MECP2, encoding methyl CpG-binding protein 2, cause Rett syndrome, the most severe autism spectrum disorder. Re-expressing Mecp2 in symptomatic Mecp2-null mice markedly improves function and longevity, providing hope that therapeutic intervention is possible in humans. To identify pathways in disease pathology for therapeutic intervention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2-null mice and isolated five suppressors that ameliorate the symptoms of Mecp2 loss. We show that a stop codon mutation in Sqle, encoding squalene epoxidase, a rate-limiting enzyme in cholesterol biosynthesis, underlies suppression in one line. Subsequently, we also show that lipid metabolism is perturbed in the brains and livers of Mecp2-null male mice. Consistently, statin drugs improve systemic perturbations of lipid metabolism, alleviate motor symptoms and confer increased longevity in Mecp2 mutant mice. Our genetic screen therefore points to cholesterol homeostasis as a potential target for the treatment of patients with Rett syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84883390784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883390784&partnerID=8YFLogxK

U2 - 10.1038/ng.2714

DO - 10.1038/ng.2714

M3 - Article

C2 - 23892605

AN - SCOPUS:84883390784

VL - 45

SP - 1013

EP - 1020

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 9

ER -